255 related articles for article (PubMed ID: 33271491)
1. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
[TBL] [Abstract][Full Text] [Related]
3. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
[TBL] [Abstract][Full Text] [Related]
5. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM
Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
[TBL] [Abstract][Full Text] [Related]
6. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
Deb S; Unwin G; Deb T
J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
[TBL] [Abstract][Full Text] [Related]
9. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
Žmuc Veranič L; Pregelj P; Jerin A
Psychogeriatrics; 2016 Nov; 16(6):384-385. PubMed ID: 26551073
[No Abstract] [Full Text] [Related]
10. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
11. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Clark WS; Street JS; Feldman PD; Breier A
J Clin Psychiatry; 2001 Jan; 62(1):34-40. PubMed ID: 11235926
[TBL] [Abstract][Full Text] [Related]
12. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010.
Okumura Y; Togo T; Fujita J
Int Psychogeriatr; 2015 Mar; 27(3):407-15. PubMed ID: 25213318
[TBL] [Abstract][Full Text] [Related]
13. Agitation and aggression in people with Alzheimer's disease.
Ballard C; Corbett A
Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
[TBL] [Abstract][Full Text] [Related]
14. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
[TBL] [Abstract][Full Text] [Related]
15. Principal components analysis of agitation outcomes in Alzheimer's disease.
Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
[TBL] [Abstract][Full Text] [Related]
16. Management of Acute Agitation and Aggression in Children and Adolescents with Pro Re Nata Oral Immediate Release Antipsychotics in the Pediatric Emergency Department.
Yip L; Aeng E; Elbe D
J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):534-541. PubMed ID: 33035069
[No Abstract] [Full Text] [Related]
17. Role of citalopram in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Keltz MA; Smith JS
Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
19. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
Davies SJ; Burhan AM; Kim D; Gerretsen P; Graff-Guerrero A; Woo VL; Kumar S; Colman S; Pollock BG; Mulsant BH; Rajji TK
J Psychopharmacol; 2018 May; 32(5):509-523. PubMed ID: 29338602
[TBL] [Abstract][Full Text] [Related]
20. Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Rosin RA; Raskind MA
Int Psychogeriatr; 2005 Jun; 17(2):313-8. PubMed ID: 16050439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
